2) The research team of Yu et al designed this study to evaluate the effects of GHRP-6, a selective growth hormone secretagogue receptor (GHSR) antagonist, on skeletal muscle under conditions of both normal physiology and doxorubicin (DOX)-induced toxicity
10 , 10.3390/jcm10122691 (2021)
While there is potential mechanistic overlap with DPP-4 inhibitors or dual GLP/GIP receptor agonists we focus the current review on GLP-1RAs due to preponderance and availability of longer-term data, as well as the significantly higher market penetrance of this drug class
Dr Babar says the peptide therapies his clinic offers are overseen by a GMC-registered doctor but, because these products are not licensed and there is "no textbook" on how to use them, it comes down to experience and clinicians like himself learning "from each other"
Phase 3 TRIUMPH Programme Retatrutide has now entered the Phase 3 TRIUMPH clinical programme, one of the most expansive trial programmes currently underway in obesity and metabolic medicine
